3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow APL-130277: new trials by email Literature Review of APL-130277 trials Research Report on APL-130277
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes APL-130277, APO-go, Apokyn - Parkinson Disease | Phase 2 | Completed | Sumitomo Pharma America, Inc. | 8 | 2017-08-22 | 2020-08-13 |
| A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes APL-130277, Placebo, Moxifloxacin - Parkinson's Disease, Off Episodes of Parkinson Disease | Phase 2 | Completed | Sumitomo Pharma America, Inc. | 48 | 2017-08-03 | 2020-08-10 |
| A Study to Examine APL-130277 in Patients With Parkinson's Disease APL-130277 - Parkinson's Disease | Phase 2 | Completed | Sumitomo Pharma America, Inc. | 20 | 2014-08-31 | 2020-07-30 |
Sumitomo Pharma America, Inc. (3)
United States (3) · Italy (1)
2016 (1)